Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.4/2354 |
Resumo: | Introduction. Sublingual immunotherapy (SLIT) with Pru p 3 can prevent severe allergic reactions to LTP-containing foods, but the standard initiation protocol is time-consuming. Objectives. Establish the safety of a novel ultra-rush initiation protocol for SLIT with Pru p 3. Methods. Prospective study comparing the side effects of the standard vs novel ultra-rush initiation protocols of SLIT with Pru p 3 in patients with anaphylaxis to LTP. Results. Fifteen patients were included (standard initiation, 5; ultra-rush initiation, 10), 80% females. All patients had oropharyngeal pruritus during initiation, 80% with spontaneous recovery, but no other gastro-intestinal, respiratory, cutaneous or systemic side effects occurred in any patient of both groups. Conclusion. The novel ultra-rush protocol halved the build-up time without increasing side effects. |
id |
RCAP_1d1fb81ec47402728ce1b3f69516a606 |
---|---|
oai_identifier_str |
oai:rihuc.huc.min-saude.pt:10400.4/2354 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effectiveHipersensibilidade AlimentarImunoterapia SublingualIntroduction. Sublingual immunotherapy (SLIT) with Pru p 3 can prevent severe allergic reactions to LTP-containing foods, but the standard initiation protocol is time-consuming. Objectives. Establish the safety of a novel ultra-rush initiation protocol for SLIT with Pru p 3. Methods. Prospective study comparing the side effects of the standard vs novel ultra-rush initiation protocols of SLIT with Pru p 3 in patients with anaphylaxis to LTP. Results. Fifteen patients were included (standard initiation, 5; ultra-rush initiation, 10), 80% females. All patients had oropharyngeal pruritus during initiation, 80% with spontaneous recovery, but no other gastro-intestinal, respiratory, cutaneous or systemic side effects occurred in any patient of both groups. Conclusion. The novel ultra-rush protocol halved the build-up time without increasing side effects.RIHUCMoura, ALPereira, CRegateiro, FSAzevedo, JTodo Bom, ACarrapatoso, I2024-02-20T16:00:00Z20192019-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.4/2354engEur Ann Allergy Clin Immunol . 2019 Sep 16;51(5):206-212.10.23822/EurAnnACI.1764-1489.99info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-02-22T08:49:21Zoai:rihuc.huc.min-saude.pt:10400.4/2354Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:10:45.157405Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective |
title |
Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective |
spellingShingle |
Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective Moura, AL Hipersensibilidade Alimentar Imunoterapia Sublingual |
title_short |
Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective |
title_full |
Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective |
title_fullStr |
Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective |
title_full_unstemmed |
Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective |
title_sort |
Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective |
author |
Moura, AL |
author_facet |
Moura, AL Pereira, C Regateiro, FS Azevedo, J Todo Bom, A Carrapatoso, I |
author_role |
author |
author2 |
Pereira, C Regateiro, FS Azevedo, J Todo Bom, A Carrapatoso, I |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
RIHUC |
dc.contributor.author.fl_str_mv |
Moura, AL Pereira, C Regateiro, FS Azevedo, J Todo Bom, A Carrapatoso, I |
dc.subject.por.fl_str_mv |
Hipersensibilidade Alimentar Imunoterapia Sublingual |
topic |
Hipersensibilidade Alimentar Imunoterapia Sublingual |
description |
Introduction. Sublingual immunotherapy (SLIT) with Pru p 3 can prevent severe allergic reactions to LTP-containing foods, but the standard initiation protocol is time-consuming. Objectives. Establish the safety of a novel ultra-rush initiation protocol for SLIT with Pru p 3. Methods. Prospective study comparing the side effects of the standard vs novel ultra-rush initiation protocols of SLIT with Pru p 3 in patients with anaphylaxis to LTP. Results. Fifteen patients were included (standard initiation, 5; ultra-rush initiation, 10), 80% females. All patients had oropharyngeal pruritus during initiation, 80% with spontaneous recovery, but no other gastro-intestinal, respiratory, cutaneous or systemic side effects occurred in any patient of both groups. Conclusion. The novel ultra-rush protocol halved the build-up time without increasing side effects. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019 2019-01-01T00:00:00Z 2024-02-20T16:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.4/2354 |
url |
http://hdl.handle.net/10400.4/2354 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Eur Ann Allergy Clin Immunol . 2019 Sep 16;51(5):206-212. 10.23822/EurAnnACI.1764-1489.99 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137757959815168 |